Clinical Trials
286 trialsCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
University of Wisconsin, Madison
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Eli Lilly and Company
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
National Cancer Institute (NCI)
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
A Study of XmAb23104 in People With Sarcoma
Memorial Sloan Kettering Cancer Center
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Radiation Therapy to Treat Musculoskeletal Tumors
St. Jude Children's Research Hospital
Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma
Royal Marsden NHS Foundation Trust
RADIOSARP
Institut Bergonié
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
GEMMK
Royal Marsden NHS Foundation Trust
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
University of Florida
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
University of Iowa
TARMIC
Institut Bergonié
LIBRETTO-121
Eli Lilly and Company
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
PEMBROSARC
Institut Bergonié
LEADER
National Taiwan University Hospital
LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)
Lytix Biopharma AS
Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Medical College of Wisconsin
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
METASARC
Institut Bergonié
TRAMUNE
Institut Bergonié
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds
Medical University of South Carolina
PROACT
Washington University School of Medicine
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
Massachusetts General Hospital
ANNOUNCE
Eli Lilly and Company
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Massachusetts General Hospital
PRIORITY
Institut Bergonié
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Ipsen
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University